Safety and efficacy of nebulised anti-inflammatory solution of alkaline hypertonic Ibuprofen (AHI) for treatment of SARS-Cov-2 Infection: A compassionate study with a comparator ar...

Autores
Kalayan, Galia; Arias, Ana Carolina; Cabello, Manuela del Valle; Nuñez, Mariela; Lumetto, Romina; Martinez Rios, Nicolás; Argañaras, Luis; Garcia, Nestor Horacio; Alasino, Roxana Valeria; Beltramo, Dante Miguel
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
This retrospective study evaluates the efficacy of inhalation therapy with alkaline hypertonic ibuprofen (AHI) inCOVID-19 positive patients compared to a control group of patients who received conventional treatment. The study was carried outat the Orías Hospital in Jujuy Province, Argentina, from June to September 2020, with final follow-up on September 30. Methods. Thestudy included 99 COVID-19 positive patients with moderate to severe disease (respiratory distress and/or hypoxemia). The controlgroup of 62 patients were treated with the protocols in force at that time, oxygen, dexamethasone and enoxaparin. The group underevaluation comprised 37 patients treated with AH), in addition to standard treatment. Findings. Result shows that the treatment withAHI formulation is safe and effective. The mean respiratory rate (RR) of the patients went from 26.3 before treatment with AHI to19.8 after treatment. On the other hand, the O2 saturation of patients before treatment with AHI showed a mean of 89.0%; at the end oftreatment, the mean was 95.8%. In patients treated with AHI, on day 14, 85% had been discharged, while in patients not treated withAHI, only 36-37% were discharged on day 23. Patients with standard treatment, without AHI, show a mortality of 38.7%, distributedevenly in the 25 days of hospitalization. The mortality of patients treated with AHI was 8.1%, observed within the first 10 days of hospitalization. Interpretation. Results show that nebulization with AHI is an anti-inflammatory therapeutic alternative for the treatmentof COVID-19 positive patients.
Fil: Kalayan, Galia. Química Luar S. R. L.; Argentina
Fil: Arias, Ana Carolina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
Fil: Cabello, Manuela del Valle. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
Fil: Nuñez, Mariela. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
Fil: Lumetto, Romina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
Fil: Martinez Rios, Nicolás. Quimica Luar S. R. L.; Argentina
Fil: Argañaras, Luis. Quimica Luar S. R. L.; Argentina
Fil: Garcia, Nestor Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
Fil: Alasino, Roxana Valeria. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Beltramo, Dante Miguel. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Materia
HYPERTONIC ALKALINE IBUPROFEN
NEBULIZATION
COVID-19 TREATMENT
ANTI-INFLAMMATORY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/211054
Acceder
id CONICETDig_a5dafe13375a16c88833a451b86b231e
oai_identifier_str oai:ri.conicet.gov.ar:11336/211054
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Safety and efficacy of nebulised anti-inflammatory solution of alkaline hypertonic Ibuprofen (AHI) for treatment of SARS-Cov-2 Infection: A compassionate study with a comparator armsKalayan, GaliaArias, Ana CarolinaCabello, Manuela del ValleNuñez, MarielaLumetto, RominaMartinez Rios, NicolásArgañaras, LuisGarcia, Nestor HoracioAlasino, Roxana ValeriaBeltramo, Dante MiguelHYPERTONIC ALKALINE IBUPROFENNEBULIZATIONCOVID-19 TREATMENTANTI-INFLAMMATORYhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3This retrospective study evaluates the efficacy of inhalation therapy with alkaline hypertonic ibuprofen (AHI) inCOVID-19 positive patients compared to a control group of patients who received conventional treatment. The study was carried outat the Orías Hospital in Jujuy Province, Argentina, from June to September 2020, with final follow-up on September 30. Methods. Thestudy included 99 COVID-19 positive patients with moderate to severe disease (respiratory distress and/or hypoxemia). The controlgroup of 62 patients were treated with the protocols in force at that time, oxygen, dexamethasone and enoxaparin. The group underevaluation comprised 37 patients treated with AH), in addition to standard treatment. Findings. Result shows that the treatment withAHI formulation is safe and effective. The mean respiratory rate (RR) of the patients went from 26.3 before treatment with AHI to19.8 after treatment. On the other hand, the O2 saturation of patients before treatment with AHI showed a mean of 89.0%; at the end oftreatment, the mean was 95.8%. In patients treated with AHI, on day 14, 85% had been discharged, while in patients not treated withAHI, only 36-37% were discharged on day 23. Patients with standard treatment, without AHI, show a mortality of 38.7%, distributedevenly in the 25 days of hospitalization. The mortality of patients treated with AHI was 8.1%, observed within the first 10 days of hospitalization. Interpretation. Results show that nebulization with AHI is an anti-inflammatory therapeutic alternative for the treatmentof COVID-19 positive patients.Fil: Kalayan, Galia. Química Luar S. R. L.; ArgentinaFil: Arias, Ana Carolina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; ArgentinaFil: Cabello, Manuela del Valle. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; ArgentinaFil: Nuñez, Mariela. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; ArgentinaFil: Lumetto, Romina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; ArgentinaFil: Martinez Rios, Nicolás. Quimica Luar S. R. L.; ArgentinaFil: Argañaras, Luis. Quimica Luar S. R. L.; ArgentinaFil: Garcia, Nestor Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; ArgentinaFil: Alasino, Roxana Valeria. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Beltramo, Dante Miguel. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaMak Periodical Library2022-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/211054Kalayan, Galia; Arias, Ana Carolina; Cabello, Manuela del Valle; Nuñez, Mariela; Lumetto, Romina; et al.; Safety and efficacy of nebulised anti-inflammatory solution of alkaline hypertonic Ibuprofen (AHI) for treatment of SARS-Cov-2 Infection: A compassionate study with a comparator arms; Mak Periodical Library; European Journal of Respiratory Medicine; 4; 2; 4-2022; 1-72633-7452CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://europeanjournalofrespiratorymedicine.com/safety-and-efficacy-of-nebulised-anti-inflammatory-solution-of-alkaline-hypertonic-ibuprofen-ahi-for-treatment-of-sars-cov-2-infection-a-compassionate-study-with-a-comparator-armsinfo:eu-repo/semantics/altIdentifier/doi/10.31488/EJRM.132info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:32:25Zoai:ri.conicet.gov.ar:11336/211054instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:32:25.345CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Safety and efficacy of nebulised anti-inflammatory solution of alkaline hypertonic Ibuprofen (AHI) for treatment of SARS-Cov-2 Infection: A compassionate study with a comparator arms
title Safety and efficacy of nebulised anti-inflammatory solution of alkaline hypertonic Ibuprofen (AHI) for treatment of SARS-Cov-2 Infection: A compassionate study with a comparator arms
spellingShingle Safety and efficacy of nebulised anti-inflammatory solution of alkaline hypertonic Ibuprofen (AHI) for treatment of SARS-Cov-2 Infection: A compassionate study with a comparator arms
Kalayan, Galia
HYPERTONIC ALKALINE IBUPROFEN
NEBULIZATION
COVID-19 TREATMENT
ANTI-INFLAMMATORY
title_short Safety and efficacy of nebulised anti-inflammatory solution of alkaline hypertonic Ibuprofen (AHI) for treatment of SARS-Cov-2 Infection: A compassionate study with a comparator arms
title_full Safety and efficacy of nebulised anti-inflammatory solution of alkaline hypertonic Ibuprofen (AHI) for treatment of SARS-Cov-2 Infection: A compassionate study with a comparator arms
title_fullStr Safety and efficacy of nebulised anti-inflammatory solution of alkaline hypertonic Ibuprofen (AHI) for treatment of SARS-Cov-2 Infection: A compassionate study with a comparator arms
title_full_unstemmed Safety and efficacy of nebulised anti-inflammatory solution of alkaline hypertonic Ibuprofen (AHI) for treatment of SARS-Cov-2 Infection: A compassionate study with a comparator arms
title_sort Safety and efficacy of nebulised anti-inflammatory solution of alkaline hypertonic Ibuprofen (AHI) for treatment of SARS-Cov-2 Infection: A compassionate study with a comparator arms
dc.creator.none.fl_str_mv Kalayan, Galia
Arias, Ana Carolina
Cabello, Manuela del Valle
Nuñez, Mariela
Lumetto, Romina
Martinez Rios, Nicolás
Argañaras, Luis
Garcia, Nestor Horacio
Alasino, Roxana Valeria
Beltramo, Dante Miguel
author Kalayan, Galia
author_facet Kalayan, Galia
Arias, Ana Carolina
Cabello, Manuela del Valle
Nuñez, Mariela
Lumetto, Romina
Martinez Rios, Nicolás
Argañaras, Luis
Garcia, Nestor Horacio
Alasino, Roxana Valeria
Beltramo, Dante Miguel
author_role author
author2 Arias, Ana Carolina
Cabello, Manuela del Valle
Nuñez, Mariela
Lumetto, Romina
Martinez Rios, Nicolás
Argañaras, Luis
Garcia, Nestor Horacio
Alasino, Roxana Valeria
Beltramo, Dante Miguel
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv HYPERTONIC ALKALINE IBUPROFEN
NEBULIZATION
COVID-19 TREATMENT
ANTI-INFLAMMATORY
topic HYPERTONIC ALKALINE IBUPROFEN
NEBULIZATION
COVID-19 TREATMENT
ANTI-INFLAMMATORY
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv This retrospective study evaluates the efficacy of inhalation therapy with alkaline hypertonic ibuprofen (AHI) inCOVID-19 positive patients compared to a control group of patients who received conventional treatment. The study was carried outat the Orías Hospital in Jujuy Province, Argentina, from June to September 2020, with final follow-up on September 30. Methods. Thestudy included 99 COVID-19 positive patients with moderate to severe disease (respiratory distress and/or hypoxemia). The controlgroup of 62 patients were treated with the protocols in force at that time, oxygen, dexamethasone and enoxaparin. The group underevaluation comprised 37 patients treated with AH), in addition to standard treatment. Findings. Result shows that the treatment withAHI formulation is safe and effective. The mean respiratory rate (RR) of the patients went from 26.3 before treatment with AHI to19.8 after treatment. On the other hand, the O2 saturation of patients before treatment with AHI showed a mean of 89.0%; at the end oftreatment, the mean was 95.8%. In patients treated with AHI, on day 14, 85% had been discharged, while in patients not treated withAHI, only 36-37% were discharged on day 23. Patients with standard treatment, without AHI, show a mortality of 38.7%, distributedevenly in the 25 days of hospitalization. The mortality of patients treated with AHI was 8.1%, observed within the first 10 days of hospitalization. Interpretation. Results show that nebulization with AHI is an anti-inflammatory therapeutic alternative for the treatmentof COVID-19 positive patients.
Fil: Kalayan, Galia. Química Luar S. R. L.; Argentina
Fil: Arias, Ana Carolina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
Fil: Cabello, Manuela del Valle. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
Fil: Nuñez, Mariela. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
Fil: Lumetto, Romina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
Fil: Martinez Rios, Nicolás. Quimica Luar S. R. L.; Argentina
Fil: Argañaras, Luis. Quimica Luar S. R. L.; Argentina
Fil: Garcia, Nestor Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
Fil: Alasino, Roxana Valeria. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Beltramo, Dante Miguel. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description This retrospective study evaluates the efficacy of inhalation therapy with alkaline hypertonic ibuprofen (AHI) inCOVID-19 positive patients compared to a control group of patients who received conventional treatment. The study was carried outat the Orías Hospital in Jujuy Province, Argentina, from June to September 2020, with final follow-up on September 30. Methods. Thestudy included 99 COVID-19 positive patients with moderate to severe disease (respiratory distress and/or hypoxemia). The controlgroup of 62 patients were treated with the protocols in force at that time, oxygen, dexamethasone and enoxaparin. The group underevaluation comprised 37 patients treated with AH), in addition to standard treatment. Findings. Result shows that the treatment withAHI formulation is safe and effective. The mean respiratory rate (RR) of the patients went from 26.3 before treatment with AHI to19.8 after treatment. On the other hand, the O2 saturation of patients before treatment with AHI showed a mean of 89.0%; at the end oftreatment, the mean was 95.8%. In patients treated with AHI, on day 14, 85% had been discharged, while in patients not treated withAHI, only 36-37% were discharged on day 23. Patients with standard treatment, without AHI, show a mortality of 38.7%, distributedevenly in the 25 days of hospitalization. The mortality of patients treated with AHI was 8.1%, observed within the first 10 days of hospitalization. Interpretation. Results show that nebulization with AHI is an anti-inflammatory therapeutic alternative for the treatmentof COVID-19 positive patients.
publishDate 2022
dc.date.none.fl_str_mv 2022-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/211054
Kalayan, Galia; Arias, Ana Carolina; Cabello, Manuela del Valle; Nuñez, Mariela; Lumetto, Romina; et al.; Safety and efficacy of nebulised anti-inflammatory solution of alkaline hypertonic Ibuprofen (AHI) for treatment of SARS-Cov-2 Infection: A compassionate study with a comparator arms; Mak Periodical Library; European Journal of Respiratory Medicine; 4; 2; 4-2022; 1-7
2633-7452
CONICET Digital
CONICET
url http://hdl.handle.net/11336/211054
identifier_str_mv Kalayan, Galia; Arias, Ana Carolina; Cabello, Manuela del Valle; Nuñez, Mariela; Lumetto, Romina; et al.; Safety and efficacy of nebulised anti-inflammatory solution of alkaline hypertonic Ibuprofen (AHI) for treatment of SARS-Cov-2 Infection: A compassionate study with a comparator arms; Mak Periodical Library; European Journal of Respiratory Medicine; 4; 2; 4-2022; 1-7
2633-7452
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://europeanjournalofrespiratorymedicine.com/safety-and-efficacy-of-nebulised-anti-inflammatory-solution-of-alkaline-hypertonic-ibuprofen-ahi-for-treatment-of-sars-cov-2-infection-a-compassionate-study-with-a-comparator-arms
info:eu-repo/semantics/altIdentifier/doi/10.31488/EJRM.132
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Mak Periodical Library
publisher.none.fl_str_mv Mak Periodical Library
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781935799500800
score 12.982451

Publicaciones similares